Abidi M Z, Ledeboer N, Banerjee A, Hari P
Division of Infectious Disease, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.
Diagn Microbiol Infect Dis. 2016 Jun;85(2):182-5. doi: 10.1016/j.diagmicrobio.2016.02.012. Epub 2016 Feb 17.
Mycobacterium mucogenicum (MM) is a rapidly growing nontuberculous mycobacterium that may rarely cause bacteremia in immune-compromised hosts. All MM cases from 2008 to 2013 were analyzed across 4 risk groups: stem cell transplantation (SCT), hematologic malignancy, solid tumors, and others. Descriptive analysis was performed, as well as comparative analysis of neutropenic patients (absolute neutrophil count ≤1000/μL) with nonneutropenic patients. Of 39 MM cases, 27 patients had undergone SCT. Neutropenia was present in 12 patients. There was a significant difference in the presence of fever at the time of MM bacteremia between neutropenic and nonneutropenic groups (92% versus 42%; P=0.005). Central venous catheter (CVC) was present in 33 cases. All patients were treated with >1 antibiotic. Most frequently used combination antibiotic regimen involved clarithromycin and amikacin. Median duration of antibiotic treatment was 42days. Bacteremia resolved in all cases with CVC removal and combination antibiotic treatment.
黏液产生分枝杆菌(MM)是一种快速生长的非结核分枝杆菌,在免疫功能低下的宿主中可能很少引起菌血症。对2008年至2013年期间的所有MM病例按4个风险组进行了分析:干细胞移植(SCT)、血液系统恶性肿瘤、实体瘤和其他。进行了描述性分析,以及中性粒细胞减少患者(绝对中性粒细胞计数≤1000/μL)与非中性粒细胞减少患者的比较分析。在39例MM病例中,27例患者接受了SCT。12例患者存在中性粒细胞减少。中性粒细胞减少组和非中性粒细胞减少组在MM菌血症发生时发热情况存在显著差异(92%对42%;P=0.005)。33例病例中存在中心静脉导管(CVC)。所有患者均接受了1种以上抗生素治疗。最常用的联合抗生素方案包括克拉霉素和阿米卡星。抗生素治疗的中位持续时间为42天。所有病例在拔除CVC并进行联合抗生素治疗后菌血症均得到缓解。